サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451618

がん診断市場レポート：製品、技術、用途、エンドユーザー、地域別、2024-2032

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がん診断市場レポート：製品、技術、用途、エンドユーザー、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん診断市場規模は2023年に1,977億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて5.1%の成長率（CAGR）を示し、2032年までに3,145億米ドルに達すると予測しています。疾病の早期発見に対する意識の高まり、ライフスタイルの変化や遺伝的素因によるがんの有病率の上昇、患者ケアを強化するための診断技術の進歩などが、市場を推進する主な要因です。

がん診断は、個人のがんの存在、タイプ、ステージを特定し判定します。これは、血液、組織、遺伝子サンプルを分析する磁気共鳴画像法（MRI）、X線、臨床検査など、さまざまな技術や手法で構成されています。これによりヘルスケア専門家は、体内のがん性増殖を正確に検出し評価することができます。また、ヘルスケアプロバイダーは、疾患の特性に合わせた介入を行うことで、患者の転帰を最適化することができます。治療方針の決定や個別化された治療戦略の開発に役立ちます。

現在、個人の間で不快感や侵襲性を最小限に抑える非侵襲的診断アプローチへの嗜好が高まっていることが、市場の成長に寄与しています。これに加えて、費用対効果が高く正確な診断技術に対する需要の高まりが、市場の成長を強化しています。これに伴い、より迅速で正確な結果を可能にするために、がん診断における人工知能（AI）、機械学習（ML）、データ分析の統合が進んでいることが、市場の成長を促進しています。これとは別に、いくつかの国の行政機関やヘルスケア当局は、世界中の大衆にがんとその診断に関する認識を広めるためのキャンペーンを実施しています。さらに、個別化された医薬品に対する需要の高まりと、世界のヘルスケア・インフラの改善が、市場に明るい展望をもたらしています。

がん診断市場の動向と促進要因：

がん罹患率の上昇

ライフスタイルの変化、環境暴露、高齢化、遺伝的素因など様々な要因により、がんの罹患率が上昇しています。遺伝子変異の蓄積や潜在的な発がん物質への曝露期間の長期化により、がんを患う人が増えています。加えて、食生活の乱れや運動不足といったライフスタイルの変化も、がんリスクを高める一因となっています。これとは別に、がんの効果的な治療のために早期発見を好む人が増えています。さらに、個人のさらなる合併症を避けるため、正確でタイムリーながん診断に対する需要の高まりが、市場の成長に寄与しています。このほか、ヘルスケアサービスへのアクセスの向上も市場の成長を後押ししています。

診断技術の進歩

各メーカーは、より高い感度、特異性、利用しやすさを提供するため、診断技術をますます進化させています。これに伴い、次世代シーケンシングやリキッドバイオプシーなどの分子・遺伝子検査技術は、さまざまな種類のがんに関連する特定のバイオマーカーの検出を可能にします。これらの技術は、腫瘍の特徴に関する洞察を提供し、カスタマイズされた治療アプローチを可能にします。これとは別に、陽電子放射断層撮影法（PET-CT）や磁気共鳴画像法（MRI）などの画像診断法の革新は、診断や病期分類に役立つ腫瘍のより詳細で正確な可視化を提供します。加えて、技術の継続的な進歩ががん診断の精度を高めており、市場の見通しは明るいです。

病気の早期発見に対する意識の高まり

がんの早期発見の重要性に対する消費者の意識の高まりが、市場の成長を後押ししています。個人は健康状態をモニターするために定期的な検診や診断検査を受けるようになっています。さらに、ヘルスケアプロバイダーや組織は、早期介入の利点について一般大衆を教育するために数多くのキャンペーンを実施しており、それによって積極的な健康追求行動を促進しています。これとは別に、早期発見は治療成績を向上させるだけでなく、進行期がんに伴う医療負担全体を軽減します。各国の行政機関やヘルスケア機関は、利用しやすい検診プログラムを提供し、タイムリーながん診断の重要性を強調しています。このような取り組みにより、個人が定期的にがん検診を受けるようになり、市場にプラスの影響を与えています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 がん診断世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 消耗品
    • 市場動向
    • 主要セグメント
      • 抗体
      • キット・試薬
      • プローブ
      • その他
    • 市場予測
  • 機器
    • 市場動向
    • 主要セグメント
      • 病理検査機器
      • 画像機器
      • 生検機器
    • 市場予測

第7章 市場内訳：技術別

  • IVD検査
    • 市場動向
    • 主要セグメント
      • ポリメラーゼ連鎖反応（PCR）
      • インサイチュハイブリダイゼーション（ISH）
      • 免疫組織化学（IHC）
      • 次世代シーケンス（NGS）
      • マイクロアレイ
      • フローサイトメトリー
      • 免疫測定法
      • その他
    • 市場予測
  • イメージング
    • 市場動向
    • 主要セグメント
      • 磁気共鳴画像法（MRI）
      • コンピュータ断層撮影（CT）
      • 陽電子放射断層撮影（PET）
      • マンモグラフィ
      • 超音波
    • 市場予測
  • 生検技術
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 乳がん
    • 市場動向
    • 市場予測
  • 肺がん
    • 市場動向
    • 市場予測
  • 大腸がん
    • 市場動向
    • 市場予測
  • メラノーマ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 病院・クリニック
    • 市場動向
    • 市場予測
  • 診断ラボ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • GE HealthCare（General Electric Company）
    • Hologic Inc.
    • Illumina Inc.
    • Koninklijke Philips N.V.
    • Pfizer Inc.
    • Qiagen N.V
    • Quest Diagnostics
    • Siemens Healthineers AG（Siemens AG）
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Cancer Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Diagnostics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Diagnostics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer Diagnostics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Cancer Diagnostics Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Cancer Diagnostics Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Cancer Diagnostics Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Cancer Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Cancer Diagnostics (Consumables) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cancer Diagnostics (Consumables) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cancer Diagnostics (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cancer Diagnostics (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cancer Diagnostics (IVD Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cancer Diagnostics (IVD Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cancer Diagnostics (Imaging) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cancer Diagnostics (Imaging) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cancer Diagnostics (Biopsy Technique) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cancer Diagnostics (Biopsy Technique) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cancer Diagnostics (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cancer Diagnostics (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cancer Diagnostics (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cancer Diagnostics (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cancer Diagnostics (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cancer Diagnostics (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cancer Diagnostics (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cancer Diagnostics (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cancer Diagnostics (Other Cancers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cancer Diagnostics (Other Cancers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cancer Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cancer Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cancer Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cancer Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cancer Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cancer Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: North America: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: North America: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: United States: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: United States: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Canada: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Canada: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Asia-Pacific: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Asia-Pacific: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: China: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: China: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Japan: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Japan: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: India: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: India: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: South Korea: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: South Korea: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Australia: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Australia: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Indonesia: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Indonesia: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Others: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Europe: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Europe: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Germany: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Germany: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: France: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: France: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: United Kingdom: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: United Kingdom: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Italy: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Italy: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Spain: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Spain: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Russia: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Russia: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Others: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Latin America: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Latin America: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Brazil: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Brazil: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Mexico: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Mexico: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Middle East and Africa: Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Middle East and Africa: Cancer Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 83: Middle East and Africa: Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Global: Cancer Diagnostics Industry: SWOT Analysis
  • Figure 85: Global: Cancer Diagnostics Industry: Value Chain Analysis
  • Figure 86: Global: Cancer Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Diagnostics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Cancer Diagnostics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Cancer Diagnostics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Cancer Diagnostics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Cancer Diagnostics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Cancer Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cancer Diagnostics Market: Competitive Structure
  • Table 8: Global: Cancer Diagnostics Market: Key Players
目次
Product Code: SR112024A6322

The global cancer diagnostics market size reached US$ 197.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 314.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The growing awareness about early detection of disease, rising prevalence of cancer due to lifestyle changes and genetic predisposition, and advancements in diagnostics techniques to enhance patient care are some of the major factors propelling the market.

Cancer diagnostics identifies and determines the presence, type, and stage of cancer among individuals. It comprises a range of techniques and technologies, such as magnetic resonance imaging (MRI), X-rays, and laboratory tests, that analyze blood, tissue, and genetic samples. It allows healthcare professionals to accurately detect and assess cancerous growths within the body. It also enables healthcare providers to optimize patient outcomes by tailoring interventions to the specific characteristics of the disease. It assists in enhancing treatment decisions and developing personalized therapeutic strategies.

At present, the increasing preference for non-invasive diagnostic approaches that minimize discomfort and invasiveness among individuals is contributing to the growth of the market. Besides this, the rising demand for cost-effective and accurate diagnostics techniques is strengthening the market growth. In line with this, the increasing integration of artificial intelligence (AI), machine learning (ML), and data analytics in cancer diagnostics to enable quicker and more accurate results is propelling the growth of the market. Apart from this, governing agencies and healthcare authorities of several countries are organizing campaigns to spread awareness about cancer and its diagnostics among the masses worldwide. Furthermore, the growing demand for personalized medicines, along with the improving healthcare infrastructure around the world, is offering a positive market outlook.

Cancer Diagnostics Market Trends/Drivers:

Rising prevalence of cancer

There is a rise in the incidence of cancer due to various factors, such as lifestyle changes, environmental exposures, aging population, and genetic predisposition. People are increasingly suffering from cancer due to accumulated genetic mutations and longer exposure periods to potential carcinogens. In addition, lifestyle changes, such as poor diet and limited physical activity, is contributing to higher cancer risk. Apart from this, people are increasingly preferring early detection for effective treatment of cancer. Additionally, the rising demand for accurate and timely cancer diagnosis to avoid further complications among individuals is contributing to the growth of the market. Besides this, the increasing accessibility to healthcare services is bolstering the growth of the market.

Advancements in diagnostics techniques

Manufacturers are increasingly advancing their diagnostic technologies to offer greater sensitivity, specificity, and accessibility. In line with this, molecular and genetic testing techniques, such as next-generation sequencing and liquid biopsies, enable the detection of specific biomarkers associated with different types of cancer. These technologies provide insights into tumor characteristics and allow customized treatment approaches. Apart from this, innovations in imaging modalities, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors that aid in diagnosis and staging. In addition, the continuous advancement in technologies enhances the precision of cancer diagnostics, which is offering a positive market outlook.

Growing awareness about early detection of diseases

Increasing consumer awareness about the importance of early cancer detection is bolstering the growth of the market. Individuals are seeking regular screenings and diagnostic tests to monitor their health conditions. Moreover, healthcare providers and organizations are organizing numerous campaigns to educate the public about the benefits of early intervention, thereby promoting proactive health-seeking behavior. Apart from this, early detection not only improves treatment outcomes but reduces the overall healthcare burden associated with advanced-stage cancer. Governing agencies and healthcare institutions of various countries are providing accessible screening programs and emphasizing the importance of timely cancer diagnosis. These initiatives encourage individuals to go for regular screening for cancer, which is positively influencing the market.

Cancer Diagnostics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cancer diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, technology, application and end user.

Breakup by Product:

Consumables

Antibodies

Kits and Reagents

Probes

Others

Instruments

Pathology-based Instruments

Imaging Instruments

Biopsy Instruments

The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables (antibodies, kits and reagents, probes, and others) and instruments (pathology-based instruments, imaging instruments, and biopsy instruments).

Consumables comprise a wide range of products used in the process of cancer diagnostics. These include reagents, test kits, stains, and antibodies that are utilized in various diagnostic procedures, such as immunohistochemistry, molecular testing, and blood-based assays. In addition, consumables play a crucial role in facilitating accurate sample processing, analysis, and interpretation. The rising adoption of consumables due to the increasing demand for diagnostic testing in cancer care is bolstering the growth of the market.

Instruments refer to the equipment and devices employed to perform diagnostic tests and procedures. This category encompasses a diverse range of technologies, such as imaging equipment, laboratory equipment, and diagnostic platforms. Apart from this, there is a rise in the innovation of diagnostic instruments to improve the accuracy, speed, and efficiency of cancer diagnostics.

Breakup by Technology:

IVD Testing

Polymerase Chain Reaction (PCR)

In Situ Hybridization (ISH)

Immunohistochemistry (IHC)

Next-generation Sequencing (NGS)

Microarrays

Flow Cytometry

Immunoassays

Others

Imaging

Magnetic Resonance Imaging (MRI)

Computed Tomography (CT)

Positron Emission Tomography (PET)

Mammography

Ultrasound

Biopsy Technique

Imaging accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes IVD testing (polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, and others), imaging (magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, and ultrasound), and biopsy technique. According to the report, imaging represented the largest segment.

Imaging technologies involve the usage of advanced medical equipment to visualize internal structures and detect abnormalities within the body. Imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, and ultrasound, provide detailed images of tumors and their size, location, and potential metastases. These technologies aid in tumor detection, staging, and treatment monitoring. In line with this, they play a vital role in guiding medical decisions, enabling precise surgical interventions, and evaluating treatment responses.

Breakup by Application:

Breast Cancer

Lung Cancer

Colorectal Cancer

Melanoma

Others

Breast cancer represents the largest market share

The report has provided a detailed breakup and analysis of the market based on the application. This includes breast cancer, lung cancer, colorectal cancer, melanoma, and others. According to the report, breast cancer represented the largest segment.

Breast cancer diagnostics comprise a wide range of methods for the early detection, diagnosis, and monitoring of breast tumors. Mammography is a widely used imaging technique that aids in detecting abnormalities, such as masses or microcalcifications. Besides this, biopsy procedures, such as core needle and fine-needle biopsies, provide tissue samples for pathological analysis that determine the nature and stage of the tumor. Molecular tests assess specific biomarkers like HER2/neu and estrogen receptor status. In addition, advanced imaging methods, such as breast MRI and molecular breast imaging, offer enhanced visualization and characterization of lesions.

Breakup by End User:

Hospitals and Clinics

Diagnostic Laboratories

Others

Hospitals and clinics hold the biggest market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, diagnostic laboratories, and others. According to the report, hospitals and clinics represented the largest segment.

Hospitals serve as comprehensive healthcare institutions that are equipped with advanced diagnostic equipment and expert medical personnel. They offer a wide range of cancer diagnostic services and provide comprehensive treatment planning based on diagnostic findings. On the other hand, clinics involve specialized cancer centers that cater to outpatient needs and often focus exclusively on cancer care. They offer diagnostics, such as mammograms and consultations, which makes it convenient for patients to receive timely evaluations. Both hospitals and clinics play pivotal roles in delivering accurate and efficient diagnostics for cancer patients.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest cancer diagnostics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the improved healthcare infrastructure. Apart from this, the rising focus on early detection of diseases among individuals is contributing to the growth of the market in the region. In line with this, the increasing awareness about cancer, along with favorable reimbursement policies, is propelling the growth of the market. Besides this, the presence of key diagnostic technology manufacturers, research institutions, and a strong network of healthcare facilities is bolstering the growth of the market in the North America region.

Competitive Landscape:

Major players are investing in research and development (R&D) activities to develop innovative diagnostic technologies. This involves exploring new biomarkers, improving imaging modalities, and enhancing the accuracy of molecular and genetic testing methods. In addition, diagnostic companies are continuously updating their existing technologies and platforms and incorporating artificial intelligence (AI) and machine learning (ML) algorithms for more accurate interpretation of diagnostic results. Apart from this, many companies are engaging in collaboration with research institutions, universities, and healthcare providers to gain expert knowledge and can access patient data for validation and improvement of diagnostic tools. Furthermore, key players are introducing new diagnostic products and services that focus on improved sensitivity, specificity, and ease of use.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Agilent Technologies Inc.

Becton Dickinson and Company

Bio-Rad Laboratories Inc.

F. Hoffmann-La Roche AG (Roche Holding AG)

GE HealthCare (General Electric Company)

Hologic Inc.

Illumina Inc.

Koninklijke Philips N.V.

Pfizer Inc.

Qiagen N.V

Quest Diagnostics

Siemens Healthineers AG (Siemens AG)

Thermo Fisher Scientific Inc.

Recent Developments:

In 2020, GE Healthcare, the leading global provider of advanced medical imaging, partnered with GenesisCare, a leading provider of integrated cancer care globally and cardiovascular care in Australia, that aimed at improving patient outcomes for the two biggest health burdens, such as cancer and heart disease.

In November 2021, Siemens Healthineers launched NAEOTOM Alpha, the world's first photon-counting CT Scanner with improved resolution and reduction in radiation dose by up to 45% for ultra-high resolution (UHR) scans.

In October 2021, Agilent Technologies Inc. announced that its PD-L1 IHC 22C3 pharmDx assay can now be used as an aid in identifying triple-negative breast cancer (TNBC) in the European Union.

Key Questions Answered in This Report

  • 1. What was the size of the global cancer diagnostics market in 2023?
  • 2. What is the expected growth rate of the global cancer diagnostics market during 2024-2032?
  • 3. What are the key factors driving the global cancer diagnostics market?
  • 4. What has been the impact of COVID-19 on the global cancer diagnostics market?
  • 5. What is the breakup of the global cancer diagnostics market based on the technology?
  • 6. What is the breakup of the global cancer diagnostics market based on the application?
  • 7. What is the breakup of the global cancer diagnostics market based on the end user?
  • 8. What are the key regions in the global cancer diagnostics market?
  • 9. Who are the key players/companies in the global cancer diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Kits and Reagents
      • 6.1.2.3 Probes
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Pathology-based Instruments
      • 6.2.2.2 Imaging Instruments
      • 6.2.2.3 Biopsy Instruments
    • 6.2.3 Market Forecast

7 Market Breakup by Technology

  • 7.1 IVD Testing
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction (PCR)
      • 7.1.2.2 In Situ Hybridization (ISH)
      • 7.1.2.3 Immunohistochemistry (IHC)
      • 7.1.2.4 Next-generation Sequencing (NGS)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Flow Cytometry
      • 7.1.2.7 Immunoassays
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Imaging
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Magnetic Resonance Imaging (MRI)
      • 7.2.2.2 Computed Tomography (CT)
      • 7.2.2.3 Positron Emission Tomography (PET)
      • 7.2.2.4 Mammography
      • 7.2.2.5 Ultrasound
    • 7.2.3 Market Forecast
  • 7.3 Biopsy Technique
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Melanoma
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GE HealthCare (General Electric Company)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Koninklijke Philips N.V.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Qiagen N.V
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Quest Diagnostics
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Siemens Healthineers AG (Siemens AG)
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Thermo Fisher Scientific Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis